Design, Synthesis, Anticancer Screening and Molecular Modelling Studies of Novel Thiazoles

A library of novel benzamide-thiazolyl-chalcone compounds was synthesized via Claisen-Schmidt reaction and spectroscopically characterized using FT-IR, 1H-NMR, 13C-NMR, LC-MS, and HR-MS. The synthesized compounds were biologically evaluated using in vitro MTT assay against different cancer cell lines (MCF-7, MDA-AMB-231, Caco-2, A549, and H1299). Amongst all compounds screened, (E)-N-(5-(3-(4-hydroxyphenyl)-3-oxoprop-1-en-1-yl)thiazol-2-yl)benzamide and (E)-N-(5-(3-(4-methoxyphenyl)-3-oxoprop-1-en-1-yl)thiazol-2-yl)benzamide showed potent anti-proliferation against breast (MCF-7) and colon cancer cell lines reaching 88.56 % and 84.36 % with IC50 values of 44.00 mu M and 58.88 mu M, respectively. All synthesized compounds exhibited no significant cytotoxicity to normal cells. Structure-activity relationship studies demonstrated the effect of electron-donating and electron-withdrawing groups on the anticancer activity of the molecules under investigation. This was also corroborated by theoretical DFT studies. Thus, these molecules may serve as potential lead candidates for further development of novel anticancer agents against breast and colon cancers. A library of 25 novel thiazole-chalcone hybrids were designed and synthesized. Anticancer activity was conducted using breast (MCF-7 and MDA-AMB-231), colon (Caco-2) and lung (A549 and H1299) cancer cell lines. Compounds (E)-N-(5-(3-(4-hydroxyphenyl)-3-oxoprop-1-en-1-yl)thiazol-2-yl)benzamide and (E)-N-(5-(3-(4-methoxyphenyl)-3-oxoprop-1-en-1-yl)thiazol-2-yl)benzamide showed 88.56 % and 84.36 % inhibition and IC50 values of 44.00 mu M, 58.88 mu M against MCF-7 cell line, respectively. Compounds (E)-N-(5-(3-(4-hydroxyphenyl)-3-oxoprop-1-en-1-yl)thiazol-2-yl)benzamide and (E)-N-(5-(3-oxo-3-phenylprop-1-en-1-yl)thiazol-2-yl)benzamide exhibited 75.83 % and 72.91 % inhibition against MDA-AMB-231 cell line.image